Premier and Octagon Announce Strategic Partnership
A new partnership between Premier Research Group and Octagon Research Solutions will expand the companies' solution sets.
Philadelphia, PA-April 29, 2008-Premier Research Group (www.premier-research.com), the international pharmaceutical services group, and Octagon Research Solutions ( www.octagonresearch.com), a leader in the electronic transformation of clinical R&D in the life sciences industry, today announce the formalization of a partnership agreement to provide a broader solution set.
This new partnership combines Octagon’s expertise in electronic submissions with Premier Research’s extensive clinical expertise across a wide array of therapeutic areas. The partnership enables Premier Research to offer Octagon’s electronic submission capabilities as part of its Regulatory Affairs services and for Octagon to offer Premier’s regulatory development and scientific strategy.
James Ottinger, vice president of global consulting and compliance for Premier Research noted, “Our partnership with Octagon broadens our services by offering Octagon’s proven expertise in the technical aspects of electronic submissions while we continue to focus on our core strengths of regulatory strategy and consulting. We are pleased to be working with an organization that also values our deep commitment to being a ‘solution provider’ for our clients.”
“Premier Research has a solid history of consistent, quality delivery that aligns with our own high standard of operation. We believe that the collaboration will ultimately provide a strong product for our valued customers,” commented Jim Walker, chairman and chief excutive officer, Octagon Research Solutions.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
